

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

NCT06747156

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Ruijin Hospital
Enrollment	66 participants

Key Eligibility Criteria

Inclusion (5)

- e18years of age at time of informed consent.
- Diagnosis of autoimmune diseases according to the corresponding disease classification criteria.
- Inadequate response to SoCs or relapsed after the treatment.
- Patients were on a stable dose of SoCs for at least 4 weeks prior to enrollment.
- Sufficient organ function.

Exclusion (10)

- Active infection, including tuberculosis, active or relapsed peptic ulcer, etc.
 - Severe hypogammaglobulinemia or IgA deficiency.
 - Active hepatitis or with a history of severe liver disease.
 - History of rapid allergic reactions, eczema or asthma that cannot be controlled by topical corticosteroids.
 - Severe cardiovascular diseases.
- ... and 5 more (see full listing online)

Locations (3 total)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Ruijin Hospital, Shanghai, China